ABS ePoster Library

P089
Topic: Non surgical treatments

Introduction: NICE guidelines support the use of neoadjuvant pertuzamab in addition to current neoadjuvant chemotherapeutic regimens as an option in the treatment of HER2+ve breast cancer. The Neosphere and Tryphaena studies demonstrated that the addition of pertuzamab increased rates of pathological complete response (PathCR) without increased rates of adverse events. The aim of this study was to see how the addition of pertuzamab affected rates of PathCR and adverse events in our population. Methods :We looked at all patients receiving neoadjuvant chemotherapy between October 2014 and January 2018. Patients with HER2+ve breast cancer were divided into two groups according to chemotherapeutic regimen: 1. FEC-T (5 fluorouracil, epirubicin, cyclophosphamide, docetaxel/abraxane) + trastuzumab (herceptin). 2. FEC-T+ trastuzumab and pertuzumab. We compared rates of PathCR, chemotherapy related admissions, chemotherapy cessation, neutropenic sepsis, neutropenia, anaemia, thrombocytopaenia, gastrointestinal disturbance, symptomatic left ventricular systolic dysfunction and death. Results: During the study period a total of 106 patients underwent neoadjuvant chemotherapy, of which there were 40 HER2+ve patients. There were 26 patients in group 1 and 14 patients in group 2 (pertuzumab). PathCR was observed in 46% of patients with trastuzumab (Group 1) and 86% with trastuzumab and pertuzumab (Group 2). This was statistically significant (p=0.02) with no significant differences in the rate of any adverse events between the two groups. Conclusion:In our population, the addition of pertuzamab in patients receiving neoadjuvant chemotherapy for HER2+ve breast cancer increases the rates of PathCR significantly without an increase in adverse events.